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Abstract
Background: In HPV infected cells p53 function is abrogated by E6 and even ectopically expressed p53 is unable
to perform tumor suppressor functions. In addition to facilitating its degradation, E6 may also inhibit p53
transactivity, though the mechanisms are still poorly understood. It has been reported that inhibition of p300, an
acetyltransferase responsible for p53 acetylation is inactivated by E6. Activation of overexpressed p53 to cause cell
growth inhibition is facilitated by its phosphorylation. Previously, we reported that non-genotoxically overexpressed
p53 in HeLa cells needs to be phosphorylated to perform its cell growth inhibitory functions. Since over expressed
p53 by itself was not activated, we hypothesized an inhibitory role for E6.
Results: Majority of reports proposes E6 mediated degradation of p53 as a possible reason for its inactivation.
However, results presented here for the first time demonstrate that overexpressed p53 is not directly associated
with E6 and therefore free, yet it is not functionally active in HPV positive cells. Also, the stability of overexpressed
p53 does not seem to be an issue because inhibition of proteasomal degradation did not increase the half-life of
overexpressed p53, which is more than endogenous p53. However, inhibition of proteasomal degradation prevents
the degradation of endogenous p53. These findings suggest that overexpressed p53 and endogenous p53 are
differentially subjected to proteasomal degradation and the reasons for this discrepancy remain unclear. Our
studies demonstrate that p53 over expression has no effect on anchorage independent cell-growth and E6 nullifies
its cell growth inhibitory effect. E6 overexpression abrogates OA induced p53 occupancy on the p21 promoter and
cell death as well. E6 did not decrease p53 protein but phospho-p53 level was significantly reduced.
Conclusion: We report for the first time that E6 de-activates p53 by inhibiting its phosphorylation. This prevents p53
binding to p21 promoter and thereby restraining its cell-growth inhibitory functions. Our study provides new evidence
indicating that viral protein E6 inhibits p53 transactivity by mechanism independent of degradation pathway.
Keywords: HPV, p53, phosphorylation, cervical cancer, E6
Background
Approximately 470,000 new cases of cervical cancer are
diagnosed every year and close to 230,000 women
worldwide die, with the majority (~80%) of incidence
occurring in developing countries. Human papilloma-
virus (HPV) infection is the main causative agent for
cervical cancer. Reports suggest that 99.7% of cervical
cancers harbor integrated HPV DNA in host cell gen-
ome [1]. HPV presence is reported in 5-11% of oral can-
cers [2]. In head and neck cancers the percentage of
HPV infection is low and it accounts for 11-25% [3-8].
In developed countries 50-70% of oropharyngeal and
tonsillar carcinomas are associated with HPV infection
[9,10]. Papillomaviruses are also reported to be present
in colon and 90% of anal cancers [11-14]. HPVs are
classified in two categories, low risk, which has less or
no potential and high risk, which has potential to cause
carcinogenesis. HPV 16 and 18 are high risk HPVs,
accounting for more than 50% of cervical cancers and
are considered as a major cause of other (head and neck
as well as anal) cancers too.
The two onco-proteins of HPV, E6 and E7 cause trans-
formation, immortalization and promote carcinogenesis
primarily by binding to important tumor suppressor’s p53
and pRb, thereby completely deregulating cell cycle check-
points [15-18]. E6 and E7 alone can also immortalize,
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any medium, provided the original work is properly cited.deregulate cell cycle and cause transformation of even pri-
mary cultures [19-21]. E6 degrades p53 by E3 ubiquitin
dependent and independent proteasomal degradation
[18,22].E6 also inhibits p53 transactivity by inhibiting acet-
ylation [23], because of its ability to bind directly and
degrade p300, an important acetyltransferase [24,25]. To
completely abrogate p53 activity E6 also degrades bax, a
major p53 downstream apoptosis inducer [26]. It has been
reported that inhibition of E6 by its specific siRNA reacti-
vates dormant p53 pathways, and the mechanisms by
which functions are restored are not clear [27-29].
Activation of many proteins is accomplished by phos-
phorylation, which is caused by group of enzymes called
kinases [30]. Concomitantly, activated proteins are kept
under check by phosphatases, thus opposing the effects
of kinases [31]. p53 being a phospho-protein is trans-acti-
vated by phosphorylation and deactivated by depho-
sphorylation [32]. Okadaic acid (OA), a specific inhibitor
of protein phosphatases, promotes phosphorylation of
p53 or its upstream kinases at various residues [33,34].
Recently, we reported that OA activates overexpressed
p53, causing cell cycle arrest and apoptosis in HeLa cells
[35]. Very little is known about the phosphorylation sta-
tus of p53 in response to its silencing by E6, except for
one study which reported that p53 is phosphorylated at
multiple residues by transiently transfected E6 [36]. In
the present investigation we demonstrate that upon OA
treatment overexpressed p53 is phosphorylated at serine
46 residue and ectopic expression of E6 promotes its
dephosphorylation. Our study provides new evidence
indicating that viral protein E6 inhibits p53 transactivity
by mechanism independent of degradation pathway.
Results
Over expression of p53 in HeLa cells
Earlier we reported the development of HeLa cells in
which p53 is conditionally overexpressed and induction
of p53 is tightly regulated by doxycycline (DOX) in a
dose dependent manner. Two p53 expressing clones
(HTet23p53 and HTet26p53) and one GFP expressing
clone (HTet43GFP) were used in this study [35]. Dox in
a dose dependent manner induces p53 protein in both
HTet23p53 (Figure 1A) and HTet26p53 (Figure 1B)
cells as compared to HTet43GFP cells (Figure 1C). Den-
sitometric analysis of bands in these blots suggests that
in comparison with non-induced state, more than 5 fold
increases in p53 level was achieved in the presence of
2000 ng/ml Dox (Figure 1D). No alteration in p53 level
was detected in HTet43GFP cells (Figure 1C) cells
under identical experimental conditions.
p53 is expressed in a time dependent manner
To study the kinetics of p53 expression single dose
(1000 ng/ml) of Dox was added for different time
durations (1 h to 48 h) and western blot was performed.
As shown in Figure 2, p53 expression was initiated
within 1 h of Dox addition and it increased progressively
up to 48 h of incubation in HTet23p53 (Figure 2A) and
HTet26p53 cells (Figure 2B). No changes in basal p53
levels were detected in HTet43GFP (Figure 2C) cells
under identical experimental conditions. At 48 h, 5-fold
increase in p53 protein was detected in HTet23p53 and
HTet26p53 cells as compared to HTet43GFP cells (Fig-
ure 2D).
Overexpressed p53 has no effect on anchorage
independent growth
The tumorigenic potential of p53 overexpressing cells
was assessed by soft agarose assay, which is often used
method for characterization of cellular growth proper-
ties. In HTet23p53 (Figure 3A) as well as HTet26p53
(Figure 3B) cells; no decrease in anchorage independent
growth was detected even after inducing p53 with upto
2000 ng/ml Dox. HTet43GFP cells served as control
(Figure 3C). No significant difference in the colony
number and size of p53 overexpressing clones as com-
pared to GFP expressing clone was visible. Dox treat-
ment slightly decreased colony number in all the three
cell lines, which may be because of long term Dox
cytotoxicity.
Overexpressed p53 is stable
To perform tumor suppressor functions p53 stability is
essential. Therefore to ascertain that overexpressed p53
is stable and it is not degraded by E6, cycloheximide
(Chx) chase experiment was performed. Cells were trea-
ted with Chx for different time points to inhibit protein
synthesis and then western blotted to detect p53. In the
presence of Chx over expressed p53 was present in sig-
nificant amount in HTet23p53 and HTet26p53 cells
(Figure 4A and 4B) even after 6 h. Under these experi-
mental conditions endogenous p53 in same cells (Figure
4A and 4B) or in HTet43GFP cells (Figure 4C)
decreased to undetectable levels just within 1 h. The
half-life of overexpressed p53 was calculated to be 6 h
as compared to that of less than 1 h for endogenous
p53 (Figure 4D).
Inhibition of proteasome promotes stability of
endogenous p53 but not for ectopically overexpressed
p53
It is very well known that p53 undergoes proteasomal
degradation. Inhibiting proteasomal degradation by two
specific inhibitors MG132 and lactacystin did not cause
accumulation of overexpressed p53 protein in
HTet23p53 as well as HTet26p53 cells upto 3 h. Treat-
ment with these inhibitors prevents degradation of
endogenous p53 protein in HTet23p53, HTet26p53 and
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5A and 5B). Taken together these results suggest that
endogenousp53 is stabilized in the presence of inhibitors
whereas overexpreseed p53 levels are not altered.
Inhibition of protein phosphatase 2A promotes cell death
and E6 reverses it by inhibiting promoter occupancy of
activated overexpressed p53
To determine whether E6 inhibits activity, p53 was first
activated by 5 nM OA, a protein phosphatase 2A
(PP2A) inhibitor. As a consequence of p53 activation
cell growth is retarded in p53 overexpressing
HTet23p53 and HTet26p53 cells compared to p53 non-
overexpressing HTet23p53, HTet26p53 or HTet43GFP
cells. Cell survival inhibitory effect was abolished by
ectopic expression of HPV 18 E6 in OA treated p53
overexpressing cells (Figure 6A). Overexpressed p53 is
not completely associated with E6 and ectopic expres-
sion of E6 does not further enhance this association,
though p53 is detected in co-immunoprecipitated com-
plex (Figure 6B). To confirm the presence of free p53 in
the lysate immunoprecipitated by E6 antibody (first IP),
second immunoprecipitation with p53 (FL-393) was
done. Interestingly, ectopic expression of E6 did not
affect the p53 protein but it does drastically decrease
the level of Ser46 phosphorylated p53 (pSer46p53) (Fig-
ure 6C). Further, to confirm that E6 mediated inhibition
of p53 phosphorylation actually is responsible for cell
growth inhibition, we performed luciferase reporter acti-
vation assay for well-known transcriptional target p21.
p21 promoter was activated by OA treatment and E6
over expression inhibits promoter activation (Figure 6D).
Overexpression of p53 causes cell death and E6
expression promotes cell survival in p53/E6 null lung
carcinoma cell line
To investigate the consequences of direct functional
interaction between p53 and E6 we transfected wild
type-p53 with or without E6 in H1299 lung carcinoma
cells, which are null for p53, and E6. p53 overexpression
decreases cell survival by 25 percent confirming it being
active in non HPV cells. OA enhances activity of p53
and therefore cell survival decreases further by addi-
tional 25 percent. Co-expression of HPV18E6 in p53
expressing cells treated with or without OA promotes
survival (Figure 7A). At protein level, as expected no
p53 is detected in these cells and it is expressed in cells
transfected with p53 plasmid. Interestingly, co-
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Figure 1 p53 expression is regulated in a dose dependent manner by Dox. (A and B) Cells treated with Dox for 48 h were harvested and
western blot for p53 was performed. (C) No induction of p53 in response to Dox was observed in HTet43GFP cells. (D) Fold induction of p53
was calculated by densitometric analysis of p53 western blot in HTet23p53, HTet26p53 and HTet43GFP cells taking control = 1with normalization
to b-Actin or b -Tubulin.
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below detection in non OA treated cells, whereas in OA
treated cells p53 is detected. Reduction of p53 level (Fig-
ure 7B, Lane 5) may be due to its degradation by E6.
Comparatively, the protein levels are higher in OA trea-
ted cells with or without E6. OA treatment enhances
pSer46p53 levels (Figure 7B, Lane 4) and E6 diminishes
OA promoted phosphorylation (Figure 7B, Lane 6).
Also, phosphorylated p53 levels decrease in the presence
of E6 (Figure 7B, Lane 6).
Discussion
p53 overexpression in HeLa cells does not exhibit cell
growth inhibitory functions whereas in non HPV posi-
tive H1299 cells it causes cell death (unpublished obser-
vation). This difference in p53 activity is likely to be
dependent on the appropriate post-translational modifi-
cations including phosphorylation status, which depends
on host cell phenotype. Also, E6 overexpression has dif-
ferential effect on p53 protein stability. In HeLa cells it
does not degrade p53 but in H1299 it completely
degrades it.
Others and we reported that activation of overex-
pressed p53 to cause cell growth inhibition is facilitated
by its phosphorylation at Ser46 [35-37]. Majority of
reports suggest the E6 or E7 mediated degradation/func-
tional impairment of p53 as possible reason for its inac-
tivation [38-40]. However, for the first time results
presented here demonstrate that overexpressed p53 is
not directly associated with E6 and therefore free, yet it
is not functionally active in HPV positive cells. Also,
overexpressed p53 has significantly increased half life
and proteasomal inhibitors do not exhibit any detectable
impact on the levels of overexpressed p53. These results
suggest that it is likely p53 activation might be inhibited
by yet unknown mechanism.
Ectopic expression of E6 does not decrease overex-
pressed p53 protein level in HeLa and H1299 cells trea-
ted with OA, which could be because of swamping out
of the available E6 and/or E6AP. This proposition
derives support from a report describing the involve-
ment of an E6 associated protein (E6 AP), which forms
a ternary complex essential for ubiquitination of p53
[41]. It is also possible that the post-translational
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Figure 2 p53 expression is regulated in a time dependent manner. (A, B and C) HTet23p53, HTet26p53 and HTet43GFP cells were treated
with 1000 ng/ml Dox for indicated time points and western blots were performed for p53. (D) Fold induction was calculated by densitometric
analysis of p53 in HTet23p53, HTet26p53 and HTet43GFP cells taking 0 h = 1 with normalization to b -Tubulin or GAPDH.
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p53 might be different and is therefore not recognizable
by the E6 and E6AP complex. The involvement of speci-
fic post-translational alterations is consistent with our
[35] and other reports [37,42]. Together, these results
suggest that expressed p53 is activated only in the pre-
sence of PP2A inhibitor and p53 phosphorylation at a
key residue is very critical for specific DNA binding as
well as promoter selection under various stress condi-
tions. Interestingly, p53 phosphorylation is diminished
by over expression of E6 in HeLa cells (Figure 6C),
which indicates that E6 causes inactivation of p53 by
inhibiting its phosphorylation. Also, E6 expression sig-
nificantly inhibits p21 promoter occupancy of the over-
expressed and activated p53, which has an impact on
cell growth (Figure 6D and 6A). Further, to confirm this
hypothesis we utilized p53 and E6 null H1299 cells.
Overexpression of p53 causes cell death (Figure 7A),
which parallels with p53 and pSer46p53 levels. OA
treatment further enhances cell killing by stabilizing p53
and pSer46p53 levels. Interestingly, E6 coexpression
causes complete degradation of p53 in non-OA treated
cells whereas in OA treated cells E6 does not reduce
p53 levels though it decreases pSer46p53 level (Figure
7B), which correlates with increased cell survival under
these condition (Figure 7A). Future studies with small
molecule activator like PRIMA that activates mutant
p53, [43] will be useful in delineating the mechanisms of
p53 activation.
Conclusion
The results presented here provide insight into differen-
tial regulation of endogenous and exogenous p53 and
the role HPV E6 plays in its phosphorylation and
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Figure 3 p53 over expression did not reduce colony number. Five thousand cells were plated in low-melting agarose containing complete
medium and allowed to grow for 30 days. (A, B and C) Cells were stained with crystal violet and photographs were taken under microscope for
HTet23p53, HTet26p53 and HTet43GFP plates. (D) Colonies were counted and average number of colonies was plotted vs Dox concentration. Bar
represents average of colonies from two representative fields (± SE).
Ajay et al. Cell & Bioscience 2012, 2:2
http://www.cellandbioscience.com/content/2/1/2
Page 5 of 11activation. These findings imply that replacement of
degraded, mutated p53 protein or functionally inacti-
vated p53 with the wild-type one will have significant
therapeutic importance only when its activation is also
achieved simultaneously. The functionality of p53
depends on the cellular background.
Materials and methods
Chemicals and antibodies
Doxycycline (Dox) and cycloheximide was purchased
from Sigma (St. Louis, MO). Tet-system approved
serum and Hygromycin solution (50 mg/ml) was pur-
chased from BD (Mountain View, CA). G418 was pur-
chased from (USB, OH). Antibodies against p53 (FL-393
goat polyclonal; DO1-HRP conjugated mouse monoclo-
nal), E6 (goat polyclonal and mouse monoclonal),
GAPDH (goat polyclonal), b-Tubulin (rabbit polyclonal)
and b-Actin (goat polyclonal) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). MG132
and Lactacystin were purchased from Calbiochem (CA).
Okadaic acid (OA) was purchased from Invitrogen Cor-
poration. Phospho-p53 Ser46 antibody (rabbit polyclo-
nal) was purchased from Cell Signaling Technology
(Danvers, MA). HRP conjugated secondary antibodies
were purchased from Santa Cruz Biotechnology.
Cell lines
HeLa and H1299 cell lines were purchased from American
Type Culture Collection (Manassas, VA) and maintained in
our in-house National Cell Repository, National Centre for
Cell Science (NCCS), Pune, India. Dox inducible cell lines
were developed by utilizing BD-TetOn system and stably
transfecting with pTetOn and pTREp53 or pBIEGFP. Dul-
becco’s minimum essential medium (DMEM) was pur-
chased from Invitrogen Corporation. The inducible cell
lines were regularly cultured in DMEM, supplemented
with 10% Tet system approved fetal bovine serum at 37°C
with 5% CO2. Inducible cell lines were maintained in 100
μg/ml of G418 and 50 μg/ml of hygromycin.
Plasmids and transfection
pTet-On, pTRE, pTK-Hyg and pBIEGFP were purchased
from BD. pC53-SN3 (p53 plasmid) was a kind gift from
Dr. Bert Vogelstein, John Hopkins, Baltimore, MD USA.
p53 fragment of pC53-SN3 was sub-cloned in BamH1
site of pTRE and was renamed as pTREp53. p21
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Figure 4 Overexpressed p53 is stable. (A and B) p53 was overexpressed with 1000 ng/ml of Dox for 48 h or not overexpressed and western
blotswere performed after indicated time of Chx treatment in HTet23p53 and HTet26p53 cells. (C) Western blot for p53 was performed with or
without addition of 1000 ng/ml Dox for 48 h followed by Chx treatment for indicated time points in HTet43GFP cells.(D) Graphical
representation of percentage of p53 protein remaining after indicated time points in HTet23p53 and HTet26p53 cells by densitometric analysis
following normalization with b-Actin. Protein percentage for 0 h Chx was taken as 100.
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Page 6 of 11luciferase was kind gift from Dr. Bert Vogelstein.
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McCance DJ, University of Rochester, USA.
Transfections were performed by Lipofectamine2000
(Invitrogen) as per manufacture’s protocols.
Soft agarose assay
Culture dish was layered with 1 ml of 0.7% agarose. Five
thousand HTet23p53, HTet26p53 and HTet43GFP cells
were plated in 0.5% low melting agarose (FMC Biopro-
ducts, ME) containing DMEM and 10% FBS with or
without Dox and incubated after layering with 1 ml com-
plete medium. Medium containing indicated concentra-
tion of Dox was changed every 4
th day. After 30 days
plates were stained with 0.1% crystal violet for 1 h and
photographed under a microscope. Colonies of more
than 50 cells were counted and graph was plotted from
the average of two independent fields from each plates.
Cell proliferation assay
Cell proliferation was determined by methylthiazole tet-
razolium (MTT) assay. Cells were seeded at the density
of 7,500 per well into 96 well plates and allowed to
adhere for 24 h. Cells were transfected with pCDNA3 or
HPV 18 E6 plasmid construct by Lipofectamine2000
reagent. Eighteen hour post transfection cells were
washed thrice with DMEM and treated with Dox in the
presence of absence of OA and further incubated for 48
h. Fifty microliter of MTT (1 mg/ml) was added to each
well and incubated for 4 h at 37°C. Hundred microliter
of 2-propanol was added and incubated in shaking con-
dition at room temperature for 10 min. Absorbance was
taken at 570 nm using 630 nm as reference filter.
Absorbance given by untreated cells was considered as
100% cell survival.
Preparation of whole cell lysate and western blotting
Following indicated treatments, cells were washed thrice
with ice-cold phosphate buffered saline (PBS) and lysed
in ice-cold lysis buffer (50 mM Tris-Cl, pH 7.5, with
120 mM NaCl, 10 mM NaF, 10 mM sodium pyropho-
sphate, 2 mM EDTA, 1 mM Na3VO4,1m MP M S F ,1 %
NP-40 and protease inhibitor cocktail (Roche Diagnos-
tics, Germany). Equal amount of protein was resolved
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Figure 5 Overexpressed p53 is not stabilized by inhibition of proteasomal degradation. Cells were treated with proteasomal inhibitors
(MG132 or Lactacystin) 1 h prior to Dox addition and incubated for 48 h. Thereafter, cells were treated with Chx for indicated time points and
western blots were performed. (A) MG132 treatment in HTet23p53 and HTet26p53 cells and p53 protein expression. (B) Lactacystin treatment in
HTet23p53 and HTet26p53 cells and p53 protein expression.
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Page 7 of 11on SDS-PAGE and western blotting was preformed as
described earlier [44]. Where ever possible blots were
stripped by incubating the membranes at 50°C for 30
min in stripping buffer (62.5 mM Tris-Cl pH 6.7, 100
mM mercaptoethanol, 2% SDS) with intermittent shak-
ing. Membranes were washed thoroughly with TBS and
reprobed with required antibodies. Otherwise gels run
in duplicates were probed for the desired proteins by
western blotting and then compiled.
Cycloheximide chase assay
HTet23p53, HTet26p53 and HTet43GFP cells grown in
a 35 mm plate were treated with 1000 ng/ml of Dox for
48 h and then 100 μg/ml cycloheximide (Chx) was
added. Cells were further incubated for indicated time
points and processed for western blotting. For inhibitor
experiments cells were treated with MG132 or Lactacys-
tin 10 μM each 48 h prior to Chx addition and har-
vested after indicated time points after Chx addition.
Immunoprecipitation
After indicated treatment cells were harvested and lysed
in RIPA buffer. Equal amount of protein (400 μg) was
taken and lysates were pre-cleared with 50 μl protein A/
G plus agarose (Invitrogen Corporation) for 30 min.
Agarose beads were pelleted and supernatant was
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Figure 6 Overexpressed p53 is functionally impaired by HPV E6. (A) HTet23p53, HTet26p53 or HTet43GFP cells were transfected with vector
or HPV18 E6 plasmid and 18 h post transfection cells were treated with OA 1 h prior to Dox addition. MTT assay was performed after 48 h. Bar
represents variations among the wells of an experiment done twice in triplicate. * Indicates P < 0.01 (B) HTet26p53 cells were transfected with
HPV18 E6 plasmid and treated as mentioned in A and immunoprecipitation was performed first with E6 antibody (first IP) and secondly by p53
antibody. p53 or E6 was detected in immunoprecipitated complex. (C) p53 post-IP (second IP) following E6 IP was performed and p53 or
phospho-p53detection by western blotting was performed. (D) Cells were transfected with p21luciferase construct with or without HPV18 E6
plasmid and treated as mentioned in A. Luciferase assay was performed and luciferase/GFP reading was plotted. Bar represents results from an
experiment done in triplicate. (± SE). * Indicates P < 0.05.
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Page 8 of 11incubated with anti-E6 goat polyclonal antibody over-
night at 4°C in an IP rotator. Fifty microliter protein A/
Gp l u sa g a r o s ew a st h e na d d e di na n t i b o d y - a n t i g e n
complex with gentle shaking for 4-5 hours at 4°C (first
IP). The immune complex bound to protein A/G plus
agarose was separated by centrifugation at 4000 rpm
and supernatant was immunoprecipitated with anti-p53
goat polyclonal antibody and as described above (second
IP). Target as well as its associated proteins was dis-
rupted from protein A/G plus agarose beads by adding
SDS gel sample buffer, resolved on SDS PAGE and pro-
cessed for western blotting [44] with mouse monoclonal
E6 and p53 antibodies.
Luciferase assay
Semi-confluent HTet23p53 and HTet26p53 cells plated
in a 12 well plate were co- transfected with pEGFPC1
and p21 luciferase plasmids by Lipofectamine2000.
Eighteen hour post-transfection 1000 ng/ml Dox was
added with or without OA and further incubated for 48
h. Luciferase assay was performed as per manufacturer’s
protocol (Amersham Biosciences). GFP reading was
taken as an internal control for normalization of trans-
fection efficiency and graphs were plotted.
Statistical Analysis
Data are expressed as the mean of three independent
experiments. Statistical comparisons are made using two
tailed students paired t-test by assuming variance is
unequal (SPSS Inc, USA) and P value < 0.05 was consid-
ered as significant.
List of Abbreviations
Dox: doxycycline; HPV: human papillomavirus; OA: okadaic acid; PP2A:
protein phosphatase 2A.
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Figure 7 Overexpressed p53 is active and is made non-functional by HPV 18 E6 in H1299, a p53 and E6 null cell line. (A) H1299 cells
were transfected with pC53-SN3 and/or HPV18 E6 plasmids and 18 h post transfection cells were treated with OA. MTT assay was performed
after 48 h. Bar represents variations among the wells of an experiment done twice in triplicate. * Indicates P < 0.01 (B) H1299 cells were
transfected with pC53-SN3 and/or HPV18E6 plasmids and 18 h post transfection cells were treated with OA for 48 h and western blot was
performed for pSer46p53 and p53.(C) Densitometric analysis was performed by normalization with p53 and ratio of pSer53 and p53 was plotted.
Ajay et al. Cell & Bioscience 2012, 2:2
http://www.cellandbioscience.com/content/2/1/2
Page 9 of 11Acknowledgements
We thank Department of Biotechnology, Government of India, for providing
research funding. A.K.A thanks Indian Council for Medical Research. A.S.M.
thanks Council of Scientific and Industrial Research for fellowship. Support
from other group members and all technical staff of NCCS is also duly
acknowledged.
Author details
1National Centre for Cell Science, NCCS Complex, Pune University Campus,
Ganeshkhind, Pune - 411007, India.
2Renal Division, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA, USA.
Authors’ contributions
AKA and MKB designed the study. AKA performed experiments in HeLa cells
and analyzed the data. ASM performed experiment with H1299 cells. AKA
and MKB wrote the manuscript and MKB supervised the project. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 October 2011 Accepted: 13 January 2012
Published: 13 January 2012
References
1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. J Pathol 1999,
189:12-19.
2. Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM: Human
papillomavirus and cancers of the upper aerodigestive tract: a review of
epidemiological and experimental evidence. Cancer Epidemiol Biomarkers
Prev 1996, 5:567-575.
3. Brandwein M, Zeitlin J, Nuovo GJ, MacConnell P, Bodian C, Urken M,
Biller H: HPV detection using “hot start” polymerase chain reaction in
patients with oral cancer: a clinicopathological study of 64 patients. Mod
Pathol 1994, 7:720-727.
4. Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL: Human
papillomavirus in head and neck squamous cell carcinomas in
nonsmokers. Arch Otolaryngol Head Neck Surg 1997, 123:513-516.
5. Gillison ML, Koch WM, Shah KV: Human papillomavirus in head and neck
squamous cell carcinoma: are some head and neck cancers a sexually
transmitted disease? Curr Opin Oncol 1999, 11:191-199.
6. Snijders PJ, Scholes AG, Hart CA, Jones AS, Vaughan ED, Woolgar JA,
Meijer CJ, Walboomers JM, Field JK: Prevalence of mucosotropic human
papillomaviruses in squamous-cell carcinoma of the head and neck. Int J
Cancer 1996, 66:464-469.
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D:
Evidence for a causal association between human papillomavirus and a
subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
8. Gillison ML, Shah KV: Human papillomavirus-associated head and neck
squamous cell carcinoma: mounting evidence for an etiologic role for
human papillomavirus in a subset of head and neck cancers. Curr Opin
Oncol 2001, 13:183-188.
9. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP: Human
papillomavirus (HPV) in head and neck cancer. An association of HPV 16
with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer 1997,
79:595-604.
10. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M: Human papillomavirus
and prognoses of patients with cancers of the upper aerodigestive tract.
Cancer 1999, 85:1903-1909.
11. Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, Boyle S,
Hankins C, Vezina S, Cote P, Macleod J, Voyer H, Forest P, Walmsley S,
Franco E: Enhanced detection and typing of human papillomavirus (HPV)
DNA in anogenital samples with PGMY primers and the linear array HPV
genotyping test. J Clin Microbiol 2006, 44:1998-2006.
12. Heideman DA, Waterboer T, Pawlita M, Delis-van DP, Nindl I, Leijte JA,
Bonfrer JM, Horenblas S, Meijer CJ, Snijders PJ: Human papillomavirus-16 is
the predominant type etiologically involved in penile squamous cell
carcinoma. J Clin Oncol 2007, 25:4550-4556.
13. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine
2006, 24(Suppl 3):S11-S25.
14. Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC:
Detection and typing of human papillomavirus DNA in penile
carcinoma: evidence for multiple independent pathways of penile
carcinogenesis. Am J Pathol 2001, 159:1211-1218.
15. Bischof O, Nacerddine K, Dejean A: Human papillomavirus oncoprotein E7
targets the promyelocytic leukemia protein and circumvents cellular
senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol
2005, 25:1013-1024.
16. Boyer SN, Wazer DE, Band V: E7 protein of human papilloma virus-16
induces degradation of retinoblastoma protein through the ubiquitin-
proteasome pathway. Cancer Res 1996, 56:4620-4624.
17. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and
E6-AP complex functions as a ubiquitin-protein ligase in the
ubiquitination of p53. Cell 1993, 75:495-505.
18. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6
oncoprotein encoded by human papillomavirus types 16 and 18
promotes the degradation of p53. Cell 1990, 63:1129-1136.
19. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT: HPV16 E6
and E7 proteins cooperate to immortalize human foreskin keratinocytes.
EMBO J 1989, 8:3905-3910.
20. Heck DV, Yee CL, Howley PM, Munger K: Efficiency of binding the
retinoblastoma protein correlates with the transforming capacity of the
E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA
1992, 89:4442-4446.
21. Toussaint-Smith E, Donner DB, Roman A: Expression of human
papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin
keratinocytes is sufficient to alter the expression of angiogenic factors.
Oncogene 2004, 23:2988-2995.
22. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP: Ubiquitin-
independent degradation of p53 mediated by high-risk human
papillomavirus protein E6. Oncogene 2007, 26:4059-4070.
23. Thomas MC, Chiang CM: E6 oncoprotein represses p53-dependent gene
activation via inhibition of protein acetylation independently of
inducing p53 degradation. Mol Cell 2005, 17:251-264.
24. Patel D, Huang SM, Baglia LA, McCance DJ: The E6 protein of human
papillomavirus type 16 binds to and inhibits co-activation by CBP and
p300. EMBO J 1999, 18:5061-5072.
25. Zimmermann H, Degenkolbe R, Bernard HU, O’Connor MJ: The human
papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity
by targeting the transcriptional coactivator CBP/p300. J Virol 1999,
73:6209-6219.
26. Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F: Inhibition of Bax
activity is crucial for the antiapoptotic function of the human
papillomavirus E6 oncoprotein. Oncogene 2006, 25:4009-4015.
27. Bousarghin L, Touze A, Gaud G, Iochmann S, Alvarez E, Reverdiau P,
Gaitan J, Jourdan ML, Sizaret PY, Coursaget PL: Inhibition of cervical cancer
cell growth by human papillomavirus virus-like particles packaged with
human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther
2009, 8:357-365.
28. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F:
siRNA targeting of the viral E6 oncogene efficiently kills human
papillomavirus-positive cancer cells. Oncogene 2003, 22:5938-5945.
29. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr: Gene silencing with
siRNA targeting E6/E7 as a therapeutic intervention in a mouse model
of cervical cancer. Gynecol Oncol 2008, 111:356-364.
30. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein
kinase complement of the human genome. Science 2002, 298:1912-1934.
31. Barford D: Molecular mechanisms of the protein serine/threonine
phosphatases. Trends Biochem Sci 1996, 21:407-412.
32. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD: ATM-dependent
activation of p53 involves dephosphorylation and association with 14-3-
3 proteins. Nat Genet 1998, 19:175-178.
33. Milczarek GJ, Chen W, Gupta A, Martinez JD, Bowden GT: Okadaic acid
mediates p53 hyperphosphorylation and growth arrest in cells with
wild-type p53 but increases aberrant mitoses in cells with non-
functional p53. Carcinogenesis 1999, 20:1043-1048.
34. Goodarzi AA, Jonnalagadda JC, Douglas P, Young D, Ye R, Moorhead GB,
Lees-Miller SP, Khanna KK: Autophosphorylation of ataxia-telangiectasia
Ajay et al. Cell & Bioscience 2012, 2:2
http://www.cellandbioscience.com/content/2/1/2
Page 10 of 11mutated is regulated by protein phosphatase 2A. EMBO J 2004,
23:4451-4461.
35. Ajay AK, Upadhyay AK, Singh S, Vijayakumar MV, Kumari R, Pandey V,
Boppana R, Bhat MK: Cdk5 phosphorylates non-genotoxically
overexpressed p53 following inhibition of PP2A to induce cell cycle
arrest/apoptosis and inhibits tumor progression. Mol Cancer 2010,
9:204-219.
36. Zhang G, Sun L, Li Z, Si L, Song T, Huang C, Zhang W: HPV-16E6 can
induce multiple site phosphorylation of p53. Oncol Rep 2009, 21:371-377.
37. Mi J, Bolesta E, Brautigan DL, Larner JM: PP2A regulates ionizing radiation-
induced apoptosis through Ser46 phosphorylation of p53. Mol Cancer
Ther 2009, 8:135-140.
38. Akutsu N, Shirasawa H, Asano T, Isono K, Simizu B: p53-Dependent and
-independent transactivation by the E6 protein of human papillomavirus
type 16. J Gen Virol 1996, 77:459-463.
39. Crook T, Fisher C, Masterson PJ, Vousden KH: Modulation of transcriptional
regulatory properties of p53 by HPV E6. Oncogene 1994, 9:1225-1230.
40. Eichten A, Westfall M, Pietenpol JA, Munger K: Stabilization and functional
impairment of the tumor suppressor p53 by the human papillomavirus
type 16 E7 oncoprotein. Virology 2002, 295:74-85.
41. Cooper B, Schneider S, Bohl J, Jiang Y, Beaudet A, Vande PS: Requirement
of E6AP and the features of human papillomavirus E6 necessary to
support degradation of p53. Virology 2003, 306:87-99.
42. Jin Z, Wallace L, Harper SQ, Yang J: PP2A:B56, a Substrate of Caspase-3,
Regulates p53-dependent and p53-independent Apoptosis during
Development. J Biol Chem 2010, 285:34493-34502.
43. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P,
Bergman J, Wiman KG, Selivanova G: Restoration of the tumor suppressor
function to mutant p53by a low-molecular-weight compound. Nat Med
2002, 8:282-288.
44. Singh S, Upadhyay AK, Ajay AK, Bhat MK: p53 regulates ERK activation in
carboplatin induced apoptosis in cervical carcinoma: a novel target of
p53 in apoptosis. FEBS Lett 2007, 581:289-295.
doi:10.1186/2045-3701-2-2
Cite this article as: Ajay et al.: Human papillomavirus 18 E6 inhibits
phosphorylation of p53 expressed in HeLa cells. Cell & Bioscience 2012
2:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ajay et al. Cell & Bioscience 2012, 2:2
http://www.cellandbioscience.com/content/2/1/2
Page 11 of 11